Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lumega-Z and Dorzolamide in Glaucoma
NCT04676126Phase 4Withdrawn
- Sponsor
- University of the Incarnate Word
- Start
- May 2021
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of dorzolamide in Open-angle glaucoma (OAG) (2 arms), sponsored by University of the Incarnate Word. Primary endpoint: Pericentral Visual Function at 3 months. Planned start May 2021; status: withdrawn.
02
Drugs
dorzolamide
03
Conditions
Open-angle glaucoma (OAG)
Beyond the preview
Go deeper on NCT04676126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04676126.